

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/117828 A1

(51) International Patent Classification:

C07D 409/04 (2006.01) A61K 31/517 (2006.01)
C07D 409/14 (2006.01) A61K 31/5377 (2006.01)
C07D 413/14 (2006.01) A61K 31/5517 (2006.01)
C07D 487/04 (2006.01) A61K 31/519 (2006.01)
C07D 487/10 (2006.01) A61K 31/5386 (2006.01)
C07D 489/04 (2006.01) A61K 31/55 (2006.01)
C07D 519/00 (2006.01) A61K 31/5395 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/057867

(22) International Filing Date:

27 November 2024 (27.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/605,348 01 December 2023 (01.12.2023) US
63/550,896 07 February 2024 (07.02.2024) US
63/658,325 10 June 2024 (10.06.2024) US

(71) Applicants: **THERAS, INC.** [US/US]; 1 Corporate Drive, South San Francisco, California 94080 (US). **LEIDOS BIOMEDICAL RESEARCH, INC.** [US/US]; P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **LAWRENCE LIVERMORE NATIONAL SECURITY, LLC** [US/US]; 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(72) Inventors: **ZHANG, Zuhui**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **WANG, Bin**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **XU, Rui**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **WALLACE, Eli**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **TURNER, David Michael**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **MACIAG, Anna Elzbieta**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **SIMANSHU, Dharendra Kumar**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **CHAN, Albert Hay Wah**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **LIAO, Tao**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Fred-

erick, Maryland 21702 (US). **YANG, Yue**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US). **PEI, Jun**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US). **LIGHTSTONE, Felice**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(74) Agent: **BUTEAU, Kristen C.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITION OF RAS

(57) Abstract: Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a Q61H, G12D, G12V, G12C, G12S, G12A, G12R, or G13D mutation or wild-type KRAS, including wild-type amplified KRAS) and treating diseases or disorders such as cancers in subjects in need thereof.

WO 2025/117828 A1